Clinical trials
Consolidation clinical trials
Below are recruiting consolidation clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07074457Recruiting
Study of two drugs for CD30+ T-cell lymphoma
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
Suzhou, JiangsuAges 18–75 - NCT07072208Recruiting
A Study of Four Drugs for Older Adults with DLBCL
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Suzhou, JiangsuAges 70 years+ - NCT07055581RecruitingPhase 2
Durvalumab after initial treatment for limited-stage lung cancer
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
Zhengzhou, HenanAges 18 years+ - NCT07058870Recruiting
Improving walking skills in progressive multiple sclerosis
This study is testing a new way to help people with progressive multiple sclerosis improve their walking and motor skills. If you have mild to moderate trouble walking and meet some other health criteria, you may be able to join.
Ferrara, FEAges 18–75 - NCT07058896Recruiting
Improving walking skills in progressive multiple sclerosis
This study tests a program to help people with progressive multiple sclerosis who have severe walking difficulty. It aims to see if the program is feasible and can improve motor skills.
Ferrara, FEAges 18–75 - NCT07059156RecruitingPhase 2/Phase 3
Chemotherapy and transplant for adult ALL
This trial is testing a combination of chemotherapy and stem cell transplant for adults with Acute Lymphoblastic Leukemia (ALL). It aims to find the best way to treat ALL and improve survival. If you are diagnosed with ALL and are between 18 and 60 years old, you may be a candidate.
Taiyuan, ShanxiAges 18–60 - NCT07053059RecruitingPhase 2
CAR T-cell therapy to prevent relapse in high-risk B-cell ALL
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
Houston, TexasAges 18 years+ - NCT07048457RecruitingPhase 2
Surgery after drug therapy for advanced bladder cancer that has spread to a few spots
This study tests whether adding surgery to remove the original bladder tumor and any remaining cancer spots can help people with advanced bladder cancer that has spread to only a few areas. It is for people who have already started a specific type of chemotherapy and whose cancer has not grown.
New Haven, ConnecticutAges 18 years+ - NCT07038629RecruitingPhase 2
Chemo, radiation, and immunotherapy for older adults with esophageal cancer
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
Tianjin, Tianjin MunicipalityAges 70–90 - NCT07014202RecruitingPhase 2
Radiation therapy after chemo-immunotherapy for lung cancer
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT06985485RecruitingPhase 2
Immunotherapy for older or frail B-ALL patients
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
Suzhou, JiangsuAges 15 years+ - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT06414148RecruitingPhase 2
Epcoritamab with or without lenalidomide and rituximab after CAR T
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
Camperdown, New South WalesAges 16 years+ - NCT06967935Recruiting
Sleep and memory study in epilepsy
This study looks at how sleep and memory work together in people with epilepsy. You will stay in the hospital for at least 4 days with a video EEG to record your brain activity while you sleep and complete memory tasks.
BronAges 18–65 - NCT06958705RecruitingPhase 2
Testing venetoclax after BTK inhibitor for CLL
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
Nanjing, JiangsuAges 18–80 - NCT06942039RecruitingEarly Phase 1
Study of two drugs for young children with aggressive brain tumors
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Calgary, AlbertaAges Up to 6 years - NCT06918002RecruitingPhase 3
Comparing elranatamab with standard care for newly diagnosed multiple myeloma
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
BrusselsAges 18–69 - NCT06834126RecruitingPhase 1
Papaverine with radiation for advanced rectal cancer
This trial tests if adding papaverine (a drug) to radiation therapy can help people with locally advanced rectal cancer avoid surgery and keep their rectum. It is for patients who have already had chemotherapy and want a non-surgical approach.
Duarte, CaliforniaAges 18 years+ - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06831981Recruiting
Heat therapy with chemo and radiation for rectal cancer
This trial tests if adding heat therapy (hyperthermia) to standard chemotherapy and radiation helps treat rectal cancer that has high-risk features. Heat therapy is thought to make cancer cells more sensitive to treatment.
Tübingen, Baden-WurttembergAges 18 years+
Hear when a new Consolidation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for consolidation?
- Yes. Clin2 currently lists 123 recruiting consolidation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a consolidation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a consolidation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.